Table 1.
Group 1 (Magnesium, n = 64) | Group 2 (Amiodarone, n = 64) | Group 3 (Control, n = 64) | P value | |
Age (years) | 58 ± 8 | 61 ± 6 | 57.6 ± 8.8 | NS |
Sex (M/F) | 40/24 | 42/22 | 52/8 | NS |
History of MI | 32 (50%) | 30 (47%) | 30 (47%) | NS |
Hypertension | 23 (36%) | 21 (33%) | 23 (36%) | NS |
Smoking | 23 (36%) | 16 (25%) | 23 (36%) | NS |
COPD | 7 (11%) | 8 (12. 5%) | 8 (12. 5%) | NS |
PTCA-Stent | 4 (6.2%) | 6 (9.4%) | 4 (6.2%) | NS |
Preoperative use of beta blocker | 21 (33%) | 23 (36%) | 21 (33%) | NS |
BSA | 1.79 ± 0.2 | 1.78 ± 0.3 | 1.78 ± 0.3 | NS |
LVEDP(mmHg) | 13.6 ± 4.2 | 16.9 ± 6.5 | 14.6 ± 4.4 | NS |
Left ventricle EF (mean %) | 45 ± 4 | 43 ± 3 | 44 ± 4 | NS |
Diabetes Mellitus | 20 (31%) | 18 (28%) | 18 (28%) | NS |
MI, myocardial infarction; COPD, chronical obstructive pulmonary disease; NYHA, New York Heart Association; PTCA, percutan transluminal coronary angioplasty; BSA, body surface area; LVEDP, left ventricle end diastolic pressure; NS, not significant (p > 0.05).